Interferon beta-1b

Interferon beta-1b

Clinical data
ATC code	L03AB08 (WHO)
Identifiers
IUPAC name Human interferon beta
CAS Number	145155-23-3
DrugBank	BTD00078
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C908H1408N246O253S6
Molar mass	20011.0 g/mol

Interferon beta-1b (marketed as Betaseron) is a drug in the interferon family used to treat the relapsing-remitting form of multiple sclerosis. It is administered by sub-cutaneous injection and has been shown to slow the advance of the affliction as well as reduce the frequency of attacks. Betaseron is manufactured by Berlex Corporation.

It is believed that Interferon-Beta based drugs achieve their beneficial effect on MS progress via their anti-inflammatory properties. Studies have also determined that Interferon-Beta improves the integrity of the blood-brain barrier (BBB)—which generally breaks down in MS patients, allowing increasing amounts of undesirable substances to reach the brain. This strengthening of the BBB may be a contributing factor to Interferon-Beta's beneficial effects. These studies were carried out in vitro, so it does not necessarily mean it works the same in people.

Closely related is Interferon beta-1a, also indicated for multiple sclerosis, and with a very similar drug profile.

Betaseron costs approximately US$1750 for 0.3 mg solution, or equivalent to 15 vials.

See also

• Interferon beta-1a
• Multiple sclerosis

External links

• betaseron.com
• Berlex
• National MS Society (USA)
• ThisIsMS - an MS community website